Celiac disease is a genetic, auto-immune disorder that affects the small intestine upon consumption of gluten. Celiac diseases may contribute to various diseases and disorders such as low bone density, neurological disorders, infertility, and certain cancers. There are no drugs available that can treat celiac diseases.

Growth in the prevalence of celiac diseases is the major factor that drives the growth of the celiac disease drugs market. In addition, the dependence on gluten rich food and trends of ready-to-use packaged food have increased the demand for the celiac disease drugs market.

Furthermore, rise in healthcare expenditure and increase in investments in celiac disease awareness programs by governments and private organizations such as National Program for the Detection and Control of Celiac Disease are anticipated to boost the market growth. However, stringent government regulations for drug approval hinder the growth. Ongoing R&D activities related to celiac disease drugs are anticipated to present new opportunities for the market.

The market is segmented on the basis of drugs and geography. Based on drugs, the market is categorized into first line of treatment and second line of treatment. The geographical breakdown of each of the aforesaid segments has been covered for North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

• The study provides an in-depth analysis of the global celiac disease drugs market with current trends and future estimations to elucidate investment pockets.
• Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
• The report provides a quantitative analysis to help stakeholders to capitalize on prevailing market opportunities.
• Extensive analysis of different segments helps understand various products of the market.
• Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.

 Key Market Segments

• By Drugs
  • First Line of Treatment
  • Second Line of Treatment
• By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • The Middle East
    • Africa

 
Key Market Players

• BiolineRx Ltd.
• Johnson & Johnson
• Bristol-Myers Squibb Company
• Pfizer Inc.
• F. Hoffmann-La Roche
• Novartis AG
• Merck & Co., Inc.
• ImmusanT, Inc.
• Innovate Biopharmaceuticals
• Immunomedics, Inc.

• CHAPTER 1: INTRODUCTION

  • 1.1. Report Description

  • 1.2. Key Market Segments

  • 1.3. Key Benefits

  • 1.4. Research Methodology

    • 1.4.1. Primary Research

    • 1.4.2. Secondary Research

    • 1.4.3. Analyst Tools and Models

• CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

• CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope

  • 3.2. Key Findings

    • 3.2.1. Top Investment Pockets

    • 3.2.2. Top Winning Strategies

  • 3.3. Porter's Five Forces Analysis

    • 3.3.1. Bargaining Power of Suppliers

    • 3.3.2. Threat of New Entrants

    • 3.3.3. Threat of Substitutes

    • 3.3.4. Competitive Rivalry

    • 3.3.5. Bargaining Power among Buyers

  • 3.5. Market Dynamics

    • 3.5.1. Drivers

    • 3.5.2. Restraints

    • 3.5.3. Opportunities

• CHAPTER 4: CELIAC DISEASE DRUGS MARKET, BY DRUGS

  • 4.1. Market Overview

    • 4.1.1 Market Size and Forecast, By Drugs

  • 4.2. First Line Of Treatment

    • 4.2.1. Key Market Trends, Growth Factors and Opportunities

    • 4.2.2. Market Size and Forecast, By Region

    • 4.2.3. Market Share Analysis, By Country

  • 4.3. Second Line Of Treatment

    • 4.3.1. Key Market Trends, Growth Factors and Opportunities

    • 4.3.2. Market Size and Forecast, By Region

    • 4.3.3. Market Share Analysis, By Country

• CHAPTER 5: CELIAC DISEASE DRUGS MARKET, BY REGION

  • 5.1. Market Overview

    • 5.1.1 Market Size and Forecast, By Region

  • 5.2. North America

    • 5.2.1. Key Market Trends and Opportunities

    • 5.2.2. Market Size and Forecast, By Drugs

    • 5.2.3. Market Size and Forecast, By Country

    • 5.2.4. U.S. Celiac Disease Drugs Market

      • 5.2.4.1. Market Size and Forecast, By Drugs

    • 5.2.5. Canada Celiac Disease Drugs Market

      • 5.2.5.1. Market Size and Forecast, By Drugs

    • 5.2.6. Mexico Celiac Disease Drugs Market

      • 5.2.6.1. Market Size and Forecast, By Drugs

  • 5.3. Europe

    • 5.3.1. Key Market Trends and Opportunities

    • 5.3.2. Market Size and Forecast, By Drugs

    • 5.3.3. Market Size and Forecast, By Country

    • 5.3.4. France Celiac Disease Drugs Market

      • 5.3.4.1. Market Size and Forecast, By Drugs

    • 5.3.5. Germany Celiac Disease Drugs Market

      • 5.3.5.1. Market Size and Forecast, By Drugs

    • 5.3.6. Italy Celiac Disease Drugs Market

      • 5.3.6.1. Market Size and Forecast, By Drugs

    • 5.3.7. Spain Celiac Disease Drugs Market

      • 5.3.7.1. Market Size and Forecast, By Drugs

    • 5.3.8. UK Celiac Disease Drugs Market

      • 5.3.8.1. Market Size and Forecast, By Drugs

    • 5.3.9. Russia Celiac Disease Drugs Market

      • 5.3.9.1. Market Size and Forecast, By Drugs

    • 5.3.10. Rest Of Europe Celiac Disease Drugs Market

      • 5.3.10.1. Market Size and Forecast, By Drugs

  • 5.4. Asia-Pacific

    • 5.4.1. Key Market Trends and Opportunities

    • 5.4.2. Market Size and Forecast, By Drugs

    • 5.4.3. Market Size and Forecast, By Country

    • 5.4.4. China Celiac Disease Drugs Market

      • 5.4.4.1. Market Size and Forecast, By Drugs

    • 5.4.5. Japan Celiac Disease Drugs Market

      • 5.4.5.1. Market Size and Forecast, By Drugs

    • 5.4.6. India Celiac Disease Drugs Market

      • 5.4.6.1. Market Size and Forecast, By Drugs

    • 5.4.7. South Korea Celiac Disease Drugs Market

      • 5.4.7.1. Market Size and Forecast, By Drugs

    • 5.4.8. Australia Celiac Disease Drugs Market

      • 5.4.8.1. Market Size and Forecast, By Drugs

    • 5.4.9. Thailand Celiac Disease Drugs Market

      • 5.4.9.1. Market Size and Forecast, By Drugs

    • 5.4.10. Malaysia Celiac Disease Drugs Market

      • 5.4.10.1. Market Size and Forecast, By Drugs

    • 5.4.11. Indonesia Celiac Disease Drugs Market

      • 5.4.11.1. Market Size and Forecast, By Drugs

    • 5.4.12. Rest of Asia Pacific Celiac Disease Drugs Market

      • 5.4.12.1. Market Size and Forecast, By Drugs

  • 5.5. LAMEA

    • 5.5.1. Key Market Trends and Opportunities

    • 5.5.2. Market Size and Forecast, By Drugs

    • 5.5.3. Market Size and Forecast, By Country

    • 5.5.4. Brazil Celiac Disease Drugs Market

      • 5.5.4.1. Market Size and Forecast, By Drugs

    • 5.5.5. South Africa Celiac Disease Drugs Market

      • 5.5.5.1. Market Size and Forecast, By Drugs

    • 5.5.6. Saudi Arabia Celiac Disease Drugs Market

      • 5.5.6.1. Market Size and Forecast, By Drugs

    • 5.5.7. UAE Celiac Disease Drugs Market

      • 5.5.7.1. Market Size and Forecast, By Drugs

    • 5.5.8. Argentina Celiac Disease Drugs Market

      • 5.5.8.1. Market Size and Forecast, By Drugs

    • 5.5.9. Rest of LAMEA Celiac Disease Drugs Market

      • 5.5.9.1. Market Size and Forecast, By Drugs

• CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction

  • 6.2. Top Winning Strategies

  • 6.3. Product Mapping Of Top 10 Player

  • 6.4. Competitive Dashboard

  • 6.5. Competitive Heatmap

  • 6.6. Top Player Positioning, 2024

• CHAPTER 7: COMPANY PROFILES

  • 7.1. F. Hoffmann-La Roche

    • 7.1.1. Company Overview

    • 7.1.2. Key Executives

    • 7.1.3. Company Snapshot

    • 7.1.4. Operating Business Segments

    • 7.1.5. Product Portfolio

    • 7.1.6. Business Performance

    • 7.1.7. Key Strategic Moves and Developments

  • 7.2. Merck And Co., Inc.

    • 7.2.1. Company Overview

    • 7.2.2. Key Executives

    • 7.2.3. Company Snapshot

    • 7.2.4. Operating Business Segments

    • 7.2.5. Product Portfolio

    • 7.2.6. Business Performance

    • 7.2.7. Key Strategic Moves and Developments

  • 7.3. Johnson And Johnson

    • 7.3.1. Company Overview

    • 7.3.2. Key Executives

    • 7.3.3. Company Snapshot

    • 7.3.4. Operating Business Segments

    • 7.3.5. Product Portfolio

    • 7.3.6. Business Performance

    • 7.3.7. Key Strategic Moves and Developments

  • 7.4. BiolineRx Ltd.

    • 7.4.1. Company Overview

    • 7.4.2. Key Executives

    • 7.4.3. Company Snapshot

    • 7.4.4. Operating Business Segments

    • 7.4.5. Product Portfolio

    • 7.4.6. Business Performance

    • 7.4.7. Key Strategic Moves and Developments

  • 7.5. Pfizer Inc.

    • 7.5.1. Company Overview

    • 7.5.2. Key Executives

    • 7.5.3. Company Snapshot

    • 7.5.4. Operating Business Segments

    • 7.5.5. Product Portfolio

    • 7.5.6. Business Performance

    • 7.5.7. Key Strategic Moves and Developments

  • 7.6. Innovate Biopharmaceuticals

    • 7.6.1. Company Overview

    • 7.6.2. Key Executives

    • 7.6.3. Company Snapshot

    • 7.6.4. Operating Business Segments

    • 7.6.5. Product Portfolio

    • 7.6.6. Business Performance

    • 7.6.7. Key Strategic Moves and Developments

  • 7.7. ImmusanT, Inc.

    • 7.7.1. Company Overview

    • 7.7.2. Key Executives

    • 7.7.3. Company Snapshot

    • 7.7.4. Operating Business Segments

    • 7.7.5. Product Portfolio

    • 7.7.6. Business Performance

    • 7.7.7. Key Strategic Moves and Developments

  • 7.8. Novartis AG

    • 7.8.1. Company Overview

    • 7.8.2. Key Executives

    • 7.8.3. Company Snapshot

    • 7.8.4. Operating Business Segments

    • 7.8.5. Product Portfolio

    • 7.8.6. Business Performance

    • 7.8.7. Key Strategic Moves and Developments

  • 7.9. Bristol-Myers Squibb Company

    • 7.9.1. Company Overview

    • 7.9.2. Key Executives

    • 7.9.3. Company Snapshot

    • 7.9.4. Operating Business Segments

    • 7.9.5. Product Portfolio

    • 7.9.6. Business Performance

    • 7.9.7. Key Strategic Moves and Developments

  • 7.10. Immunomedics, Inc.

    • 7.10.1. Company Overview

    • 7.10.2. Key Executives

    • 7.10.3. Company Snapshot

    • 7.10.4. Operating Business Segments

    • 7.10.5. Product Portfolio

    • 7.10.6. Business Performance

    • 7.10.7. Key Strategic Moves and Developments

• LIST OF TABLES

• TABLE 1. GLOBAL CELIAC DISEASE DRUGS MARKET, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 2. GLOBAL CELIAC DISEASE DRUGS MARKET FOR FIRST LINE OF TREATMENT, BY REGION, 2025-2033 ($MILLION)
• TABLE 3. GLOBAL CELIAC DISEASE DRUGS MARKET FOR SECOND LINE OF TREATMENT, BY REGION, 2025-2033 ($MILLION)
• TABLE 4. GLOBAL CELIAC DISEASE DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
• TABLE 5. NORTH AMERICA CELIAC DISEASE DRUGS, BY REGION, 2025-2033 ($MILLION)
• TABLE 6. NORTH AMERICA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 7. U.S. CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 8. CANADA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 9. MEXICO CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 10. EUROPE CELIAC DISEASE DRUGS, BY REGION, 2025-2033 ($MILLION)
• TABLE 11. EUROPE CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 12. FRANCE CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 13. GERMANY CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 14. ITALY CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 15. SPAIN CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 16. UK CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 17. RUSSIA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 18. REST OF EUROPE CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 19. ASIA-PACIFIC CELIAC DISEASE DRUGS, BY REGION, 2025-2033 ($MILLION)
• TABLE 20. ASIA-PACIFIC CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 21. CHINA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 22. JAPAN CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 23. INDIA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 24. SOUTH KOREA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 25. AUSTRALIA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 26. THAILAND CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 27. MALAYSIA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 28. INDONESIA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 29. REST OF ASIA PACIFIC CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 30. LAMEA CELIAC DISEASE DRUGS, BY REGION, 2025-2033 ($MILLION)
• TABLE 31. LAMEA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 32. BRAZIL CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 33. SOUTH AFRICA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 34. SAUDI ARABIA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 35. UAE CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 36. ARGENTINA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 37. REST OF LAMEA CELIAC DISEASE DRUGS, BY DRUGS, 2025-2033 ($MILLION)
• TABLE 38. F. HOFFMANN-LA ROCHE: KEY EXECUTIVES
• TABLE 39. F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
• TABLE 40. F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS
• TABLE 41. F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
• TABLE 42. F. HOFFMANN-LA ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 43. MERCK AND CO., INC.: KEY EXECUTIVES
• TABLE 44. MERCK AND CO., INC.: COMPANY SNAPSHOT
• TABLE 45. MERCK AND CO., INC.: OPERATING SEGMENTS
• TABLE 46. MERCK AND CO., INC.: PRODUCT PORTFOLIO
• TABLE 47. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 48. JOHNSON AND JOHNSON: KEY EXECUTIVES
• TABLE 49. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
• TABLE 50. JOHNSON AND JOHNSON: OPERATING SEGMENTS
• TABLE 51. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
• TABLE 52. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 53. BIOLINERX LTD.: KEY EXECUTIVES
• TABLE 54. BIOLINERX LTD.: COMPANY SNAPSHOT
• TABLE 55. BIOLINERX LTD.: OPERATING SEGMENTS
• TABLE 56. BIOLINERX LTD.: PRODUCT PORTFOLIO
• TABLE 57. BIOLINERX LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 58. PFIZER INC.: KEY EXECUTIVES
• TABLE 59. PFIZER INC.: COMPANY SNAPSHOT
• TABLE 60. PFIZER INC.: OPERATING SEGMENTS
• TABLE 61. PFIZER INC.: PRODUCT PORTFOLIO
• TABLE 62. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 63. INNOVATE BIOPHARMACEUTICALS: KEY EXECUTIVES
• TABLE 64. INNOVATE BIOPHARMACEUTICALS: COMPANY SNAPSHOT
• TABLE 65. INNOVATE BIOPHARMACEUTICALS: OPERATING SEGMENTS
• TABLE 66. INNOVATE BIOPHARMACEUTICALS: PRODUCT PORTFOLIO
• TABLE 67. INNOVATE BIOPHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 68. IMMUSANT, INC.: KEY EXECUTIVES
• TABLE 69. IMMUSANT, INC.: COMPANY SNAPSHOT
• TABLE 70. IMMUSANT, INC.: OPERATING SEGMENTS
• TABLE 71. IMMUSANT, INC.: PRODUCT PORTFOLIO
• TABLE 72. IMMUSANT, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 73. NOVARTIS AG: KEY EXECUTIVES
• TABLE 74. NOVARTIS AG: COMPANY SNAPSHOT
• TABLE 75. NOVARTIS AG: OPERATING SEGMENTS
• TABLE 76. NOVARTIS AG: PRODUCT PORTFOLIO
• TABLE 77. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 78. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
• TABLE 79. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
• TABLE 80. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
• TABLE 81. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
• TABLE 82. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 83. IMMUNOMEDICS, INC.: KEY EXECUTIVES
• TABLE 84. IMMUNOMEDICS, INC.: COMPANY SNAPSHOT
• TABLE 85. IMMUNOMEDICS, INC.: OPERATING SEGMENTS
• TABLE 86. IMMUNOMEDICS, INC.: PRODUCT PORTFOLIO
• TABLE 87. IMMUNOMEDICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

• LIST OF FIGURES

• FIGURE 1. GLOBAL CELIAC DISEASE DRUGS MARKET SEGMENTATION
• FIGURE 2. GLOBAL CELIAC DISEASE DRUGS MARKET
• FIGURE 3. SEGMENTATION CELIAC DISEASE DRUGS MARKET
• FIGURE 4. TOP INVESTMENT POCKET IN CELIAC DISEASE DRUGS MARKET
• FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
• FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
• FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
• FIGURE 8. LOW THREAT OF SUBSTITUTION
• FIGURE 9. HIGH COMPETITIVE RIVALRY
• FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCELIAC DISEASE DRUGS MARKET
• FIGURE 11. CELIAC DISEASE DRUGS MARKET SEGMENTATION, BY BY DRUGS
• FIGURE 12. CELIAC DISEASE DRUGS MARKET FOR FIRST LINE OF TREATMENT, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 13. CELIAC DISEASE DRUGS MARKET FOR SECOND LINE OF TREATMENT, BY COUNTRY, 2025-2033 ($MILLION)
• FIGURE 14. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
• FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
• FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
• FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 18. COMPETITIVE DASHBOARD
• FIGURE 19. COMPETITIVE HEATMAP: CELIAC DISEASE DRUGS MARKET
• FIGURE 20. TOP PLAYER POSITIONING, 2024
• FIGURE 21. F. HOFFMANN-LA ROCHE: NET SALES, 2022-2024 ($MILLION)
• FIGURE 22. F. HOFFMANN-LA ROCHE: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 23. F. HOFFMANN-LA ROCHE: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 24. MERCK AND CO., INC.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 25. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 26. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 27. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
• FIGURE 28. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 29. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 30. BIOLINERX LTD.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 31. BIOLINERX LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 32. BIOLINERX LTD.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 33. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 34. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 35. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 36. INNOVATE BIOPHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
• FIGURE 37. INNOVATE BIOPHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 38. INNOVATE BIOPHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 39. IMMUSANT, INC.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 40. IMMUSANT, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 41. IMMUSANT, INC.: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 42. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
• FIGURE 43. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 44. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 45. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2022-2024 ($MILLION)
• FIGURE 46. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 47. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
• FIGURE 48. IMMUNOMEDICS, INC.: NET SALES, 2022-2024 ($MILLION)
• FIGURE 49. IMMUNOMEDICS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
• FIGURE 50. IMMUNOMEDICS, INC.: REVENUE SHARE, BY REGION, 2024 (%)